Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Sandoz business dynamics continue to normalize,
benefitting from a lower prior year comparison
SANDOZ
Sandoz stabilizing
Q1 sales USD 2.4 bn (+8%) driven by Europe (+9%)
■
Retail USD 1.8 bn (+11%)
■
Biopharma USD 0.5 bn (+7%)
◉
Benefitting from low PY comparator
Core Operating Income USD 538m (+26%)
Benefitting from low PY comp (due to cough & cold season)
Assumptions for FY
Continuing geopolitical uncertainty, price erosion,
inflationary pressures
Solid base for strong mid-term growth
Driven by biosimilars, significant LOE opportunity
Targeting USD 80bn originator sales (2030)
Critical success factors on track
Leading biosimilars pipeline: 15+ assets
Manufacturing scale and expertise
✓ Development and regulatory experience
Global footprint
Experience in commercialization
Leading in Europe; expanding US, ROW
Strategic review of Sandoz continues to progress, update expected at latest by end 2022
All % growth relate to cc unless otherwise stated
16 Investor Relations | Q1 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation